The Multiple Sclerosis at Home Access Program (MAHA): New Challenges for Those Living with Multiple Sclerosis and Significant Disability during the COVID-19 Pandemic
Background: Abundant evidence supports disparity in health care delivery for persons with disability. These disparities may be magnified...
COVID-19 Vaccine Response in People with MS Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy
Background: COVID-19 is a potentially fatal respiratory illness, caused by the novel coronavirus, SARS-CoV-2, which developed into the...